Supplementary Methods S1 from Axicabtagene Ciloleucel in Combination With the 4-1BB Agonist Utomilumab in Patients With Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results From ZUMA-11 Article Swipe

View

Michael D. Jain , David B. Miklos , Caron A. Jacobson , John M. Timmerman , Jennifer Sun , Jenny Nater , Xiang Fang , Ankit Patel , Madison Davis , Darren Heeke , Tan Trinh , Mike Mattie , Frank Neumann , Jenny Kim , Christina To , Simone Filosto , Ran Reshef ·

YOU? · · 2024 · Open Access · · DOI: https://doi.org/10.1158/1078-0432.27033925.v1

SUPPLEMENTARY METHODS

Related Topics

Concepts

Refractory (planetary science) Lymphoma Agonist Medicine Phase (matter) Cancer research Internal medicine Materials science Chemistry Receptor Metallurgy Organic chemistry

Metadata

Type: preprint
Language: en
Landing Page: https://doi.org/10.1158/1078-0432.27033925.v1
OA Status: gold
Related Works: 10
OpenAlex ID: https://openalex.org/W4402796068

All OpenAlex metadata

Raw OpenAlex JSON

OpenAlex ID: https://openalex.org/W4402796068

Canonical identifier for this work in OpenAlex
DOI: https://doi.org/10.1158/1078-0432.27033925.v1

Digital Object Identifier
Title: Supplementary Methods S1 from Axicabtagene Ciloleucel in Combination With the 4-1BB Agonist Utomilumab in Patients With Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results From ZUMA-11

Work title
Type: preprint

OpenAlex work type
Language: en

Primary language
Publication year: 2024

Year of publication
Publication date: 2024-09-16

Full publication date if available
Authors: Michael D. Jain, David B. Miklos, Caron A. Jacobson, John M. Timmerman, Jennifer Sun, Jenny Nater, Xiang Fang, Ankit Patel, Madison Davis, Darren Heeke, Tan Trinh, Mike Mattie, Frank Neumann, Jenny Kim, Christina To, Simone Filosto, Ran Reshef

List of authors in order
Landing page: https://doi.org/10.1158/1078-0432.27033925.v1

Publisher landing page
Open access: Yes

Whether a free full text is available
OA status: gold

Open access status per OpenAlex
OA URL: https://doi.org/10.1158/1078-0432.27033925.v1

Direct OA link when available
Concepts: Refractory (planetary science), Lymphoma, Agonist, Medicine, Phase (matter), Cancer research, Internal medicine, Materials science, Chemistry, Receptor, Metallurgy, Organic chemistry

Top concepts (fields/topics) attached by OpenAlex
Cited by: 0

Total citation count in OpenAlex
Related works (count): 10

Other works algorithmically related by OpenAlex

Full payload

id	https://openalex.org/W4402796068
doi	https://doi.org/10.1158/1078-0432.27033925.v1
ids.doi	https://doi.org/10.1158/1078-0432.27033925.v1
ids.openalex	https://openalex.org/W4402796068
fwci	0.0
type	preprint
title	Supplementary Methods S1 from Axicabtagene Ciloleucel in Combination With the 4-1BB Agonist Utomilumab in Patients With Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results From ZUMA-11
biblio.issue
biblio.volume
biblio.last_page
biblio.first_page
topics[0].id	https://openalex.org/T11491
topics[0].field.id	https://openalex.org/fields/27
topics[0].field.display_name	Medicine
topics[0].score	0.9997000098228455
topics[0].domain.id	https://openalex.org/domains/4
topics[0].domain.display_name	Health Sciences
topics[0].subfield.id	https://openalex.org/subfields/2730
topics[0].subfield.display_name	Oncology
topics[0].display_name	CAR-T cell therapy research
topics[1].id	https://openalex.org/T10185
topics[1].field.id	https://openalex.org/fields/27
topics[1].field.display_name	Medicine
topics[1].score	0.9894000291824341
topics[1].domain.id	https://openalex.org/domains/4
topics[1].domain.display_name	Health Sciences
topics[1].subfield.id	https://openalex.org/subfields/2734
topics[1].subfield.display_name	Pathology and Forensic Medicine
topics[1].display_name	Lymphoma Diagnosis and Treatment
topics[2].id	https://openalex.org/T11157
topics[2].field.id	https://openalex.org/fields/27
topics[2].field.display_name	Medicine
topics[2].score	0.9527999758720398
topics[2].domain.id	https://openalex.org/domains/4
topics[2].domain.display_name	Health Sciences
topics[2].subfield.id	https://openalex.org/subfields/2716
topics[2].subfield.display_name	Genetics
topics[2].display_name	Chronic Lymphocytic Leukemia Research
is_xpac	False
apc_list
apc_paid
concepts[0].id	https://openalex.org/C142424586
concepts[0].level	2
concepts[0].score	0.7330713272094727
concepts[0].wikidata	https://www.wikidata.org/wiki/Q7307572
concepts[0].display_name	Refractory (planetary science)
concepts[1].id	https://openalex.org/C2779338263
concepts[1].level	2
concepts[1].score	0.5353257060050964
concepts[1].wikidata	https://www.wikidata.org/wiki/Q208414
concepts[1].display_name	Lymphoma
concepts[2].id	https://openalex.org/C2778938600
concepts[2].level	3
concepts[2].score	0.5204986929893494
concepts[2].wikidata	https://www.wikidata.org/wiki/Q389934
concepts[2].display_name	Agonist
concepts[3].id	https://openalex.org/C71924100
concepts[3].level	0
concepts[3].score	0.5042003393173218
concepts[3].wikidata	https://www.wikidata.org/wiki/Q11190
concepts[3].display_name	Medicine
concepts[4].id	https://openalex.org/C44280652
concepts[4].level	2
concepts[4].score	0.42241621017456055
concepts[4].wikidata	https://www.wikidata.org/wiki/Q104837
concepts[4].display_name	Phase (matter)
concepts[5].id	https://openalex.org/C502942594
concepts[5].level	1
concepts[5].score	0.3951323628425598
concepts[5].wikidata	https://www.wikidata.org/wiki/Q3421914
concepts[5].display_name	Cancer research
concepts[6].id	https://openalex.org/C126322002
concepts[6].level	1
concepts[6].score	0.3746193051338196
concepts[6].wikidata	https://www.wikidata.org/wiki/Q11180
concepts[6].display_name	Internal medicine
concepts[7].id	https://openalex.org/C192562407
concepts[7].level	0
concepts[7].score	0.2512813210487366
concepts[7].wikidata	https://www.wikidata.org/wiki/Q228736
concepts[7].display_name	Materials science
concepts[8].id	https://openalex.org/C185592680
concepts[8].level	0
concepts[8].score	0.17047199606895447
concepts[8].wikidata	https://www.wikidata.org/wiki/Q2329
concepts[8].display_name	Chemistry
concepts[9].id	https://openalex.org/C170493617
concepts[9].level	2
concepts[9].score	0.09684163331985474
concepts[9].wikidata	https://www.wikidata.org/wiki/Q208467
concepts[9].display_name	Receptor
concepts[10].id	https://openalex.org/C191897082
concepts[10].level	1
concepts[10].score	0.04212230443954468
concepts[10].wikidata	https://www.wikidata.org/wiki/Q11467
concepts[10].display_name	Metallurgy
concepts[11].id	https://openalex.org/C178790620
concepts[11].level	1
concepts[11].score	0.0
concepts[11].wikidata	https://www.wikidata.org/wiki/Q11351
concepts[11].display_name	Organic chemistry
keywords[0].id	https://openalex.org/keywords/refractory
keywords[0].score	0.7330713272094727
keywords[0].display_name	Refractory (planetary science)
keywords[1].id	https://openalex.org/keywords/lymphoma
keywords[1].score	0.5353257060050964
keywords[1].display_name	Lymphoma
keywords[2].id	https://openalex.org/keywords/agonist
keywords[2].score	0.5204986929893494
keywords[2].display_name	Agonist
keywords[3].id	https://openalex.org/keywords/medicine
keywords[3].score	0.5042003393173218
keywords[3].display_name	Medicine
keywords[4].id	https://openalex.org/keywords/phase
keywords[4].score	0.42241621017456055
keywords[4].display_name	Phase (matter)
keywords[5].id	https://openalex.org/keywords/cancer-research
keywords[5].score	0.3951323628425598
keywords[5].display_name	Cancer research
keywords[6].id	https://openalex.org/keywords/internal-medicine
keywords[6].score	0.3746193051338196
keywords[6].display_name	Internal medicine
keywords[7].id	https://openalex.org/keywords/materials-science
keywords[7].score	0.2512813210487366
keywords[7].display_name	Materials science
keywords[8].id	https://openalex.org/keywords/chemistry
keywords[8].score	0.17047199606895447
keywords[8].display_name	Chemistry
keywords[9].id	https://openalex.org/keywords/receptor
keywords[9].score	0.09684163331985474
keywords[9].display_name	Receptor
keywords[10].id	https://openalex.org/keywords/metallurgy
keywords[10].score	0.04212230443954468
keywords[10].display_name	Metallurgy
language	en
locations[0].id	doi:10.1158/1078-0432.27033925.v1
locations[0].is_oa	True
locations[0].source
locations[0].license	cc-by
locations[0].pdf_url
locations[0].version	acceptedVersion
locations[0].raw_type	posted-content
locations[0].license_id	https://openalex.org/licenses/cc-by
locations[0].is_accepted	True
locations[0].is_published	False
locations[0].raw_source_name
locations[0].landing_page_url	https://doi.org/10.1158/1078-0432.27033925.v1
locations[1].id	pmh:oai:figshare.com:article/27033925
locations[1].is_oa	True
locations[1].source.id	https://openalex.org/S4306400572
locations[1].source.issn
locations[1].source.type	repository
locations[1].source.is_oa	False
locations[1].source.issn_l
locations[1].source.is_core	False
locations[1].source.is_in_doaj	False
locations[1].source.display_name	OPAL (Open@LaTrobe) (La Trobe University)
locations[1].source.host_organization	https://openalex.org/I196829312
locations[1].source.host_organization_name	La Trobe University
locations[1].source.host_organization_lineage	https://openalex.org/I196829312
locations[1].license	cc-by
locations[1].pdf_url
locations[1].version	submittedVersion
locations[1].raw_type	Text
locations[1].license_id	https://openalex.org/licenses/cc-by
locations[1].is_accepted	False
locations[1].is_published	False
locations[1].raw_source_name
locations[1].landing_page_url	https://figshare.com/articles/journal_contribution/Supplementary_Methods_S1_from_Axicabtagene_Ciloleucel_in_Combination_With_the_4-1BB_Agonist_Utomilumab_in_Patients_With_Relapsed_Refractory_Large_B-Cell_Lymphoma_Phase_1_Results_From_ZUMA-11/27033925
indexed_in	crossref
authorships[0].author.id	https://openalex.org/A5004321777
authorships[0].author.orcid	https://orcid.org/0000-0002-7789-1257
authorships[0].author.display_name	Michael D. Jain
authorships[0].author_position	first
authorships[0].raw_author_name	Michael D. Jain
authorships[0].is_corresponding	False
authorships[1].author.id	https://openalex.org/A5081926380
authorships[1].author.orcid	https://orcid.org/0000-0003-0717-4305
authorships[1].author.display_name	David B. Miklos
authorships[1].author_position	middle
authorships[1].raw_author_name	David B. Miklos
authorships[1].is_corresponding	False
authorships[2].author.id	https://openalex.org/A5037526878
authorships[2].author.orcid	https://orcid.org/0000-0002-0180-0654
authorships[2].author.display_name	Caron A. Jacobson
authorships[2].author_position	middle
authorships[2].raw_author_name	Caron A. Jacobson
authorships[2].is_corresponding	False
authorships[3].author.id	https://openalex.org/A5066129729
authorships[3].author.orcid	https://orcid.org/0000-0003-4104-8943
authorships[3].author.display_name	John M. Timmerman
authorships[3].author_position	middle
authorships[3].raw_author_name	John M. Timmerman
authorships[3].is_corresponding	False
authorships[4].author.id	https://openalex.org/A5085588647
authorships[4].author.orcid	https://orcid.org/0009-0008-8649-3817
authorships[4].author.display_name	Jennifer Sun
authorships[4].author_position	middle
authorships[4].raw_author_name	Jennifer Sun
authorships[4].is_corresponding	False
authorships[5].author.id	https://openalex.org/A5089893629
authorships[5].author.orcid	https://orcid.org/0000-0001-9495-0653
authorships[5].author.display_name	Jenny Nater
authorships[5].author_position	middle
authorships[5].raw_author_name	Jenny Nater
authorships[5].is_corresponding	False
authorships[6].author.id	https://openalex.org/A5103244256
authorships[6].author.orcid	https://orcid.org/0009-0006-3958-990X
authorships[6].author.display_name	Xiang Fang
authorships[6].author_position	middle
authorships[6].raw_author_name	Xiang Fang
authorships[6].is_corresponding	False
authorships[7].author.id	https://openalex.org/A5059143302
authorships[7].author.orcid	https://orcid.org/0009-0000-2105-2262
authorships[7].author.display_name	Ankit Patel
authorships[7].author_position	middle
authorships[7].raw_author_name	Ankit Patel
authorships[7].is_corresponding	False
authorships[8].author.id	https://openalex.org/A5043113298
authorships[8].author.orcid	https://orcid.org/0000-0002-1293-8974
authorships[8].author.display_name	Madison Davis
authorships[8].author_position	middle
authorships[8].raw_author_name	Madison Davis
authorships[8].is_corresponding	False
authorships[9].author.id	https://openalex.org/A5023097423
authorships[9].author.orcid	https://orcid.org/0009-0006-3790-5227
authorships[9].author.display_name	Darren Heeke
authorships[9].author_position	middle
authorships[9].raw_author_name	Darren Heeke
authorships[9].is_corresponding	False
authorships[10].author.id	https://openalex.org/A5037848458
authorships[10].author.orcid	https://orcid.org/0009-0000-8980-3579
authorships[10].author.display_name	Tan Trinh
authorships[10].author_position	middle
authorships[10].raw_author_name	Tan Trinh
authorships[10].is_corresponding	False
authorships[11].author.id	https://openalex.org/A5025066483
authorships[11].author.orcid	https://orcid.org/0000-0003-0868-3865
authorships[11].author.display_name	Mike Mattie
authorships[11].author_position	middle
authorships[11].raw_author_name	Mike Mattie
authorships[11].is_corresponding	False
authorships[12].author.id	https://openalex.org/A5004936522
authorships[12].author.orcid	https://orcid.org/0009-0001-0995-1537
authorships[12].author.display_name	Frank Neumann
authorships[12].author_position	middle
authorships[12].raw_author_name	Frank Neumann
authorships[12].is_corresponding	False
authorships[13].author.id	https://openalex.org/A5069450479
authorships[13].author.orcid	https://orcid.org/0009-0008-6816-1499
authorships[13].author.display_name	Jenny Kim
authorships[13].author_position	middle
authorships[13].raw_author_name	Jenny J. Kim
authorships[13].is_corresponding	False
authorships[14].author.id	https://openalex.org/A5019726727
authorships[14].author.orcid	https://orcid.org/0000-0001-7164-8072
authorships[14].author.display_name	Christina To
authorships[14].author_position	middle
authorships[14].raw_author_name	Christina To
authorships[14].is_corresponding	False
authorships[15].author.id	https://openalex.org/A5037111172
authorships[15].author.orcid	https://orcid.org/0000-0002-7854-998X
authorships[15].author.display_name	Simone Filosto
authorships[15].author_position	middle
authorships[15].raw_author_name	Simone Filosto
authorships[15].is_corresponding	False
authorships[16].author.id	https://openalex.org/A5085167557
authorships[16].author.orcid	https://orcid.org/0000-0003-2185-9546
authorships[16].author.display_name	Ran Reshef
authorships[16].author_position	last
authorships[16].raw_author_name	Ran Reshef
authorships[16].is_corresponding	False
has_content.pdf	False
has_content.grobid_xml	False
is_paratext	False
open_access.is_oa	True
open_access.oa_url	https://doi.org/10.1158/1078-0432.27033925.v1
open_access.oa_status	gold
open_access.any_repository_has_fulltext	False
created_date	2025-10-10T00:00:00
display_name	Supplementary Methods S1 from Axicabtagene Ciloleucel in Combination With the 4-1BB Agonist Utomilumab in Patients With Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results From ZUMA-11
has_fulltext	False
is_retracted	False
updated_date	2025-11-06T03:46:38.306776
primary_topic.id	https://openalex.org/T11491
primary_topic.field.id	https://openalex.org/fields/27
primary_topic.field.display_name	Medicine
primary_topic.score	0.9997000098228455
primary_topic.domain.id	https://openalex.org/domains/4
primary_topic.domain.display_name	Health Sciences
primary_topic.subfield.id	https://openalex.org/subfields/2730
primary_topic.subfield.display_name	Oncology
primary_topic.display_name	CAR-T cell therapy research
related_works	https://openalex.org/W1976377219, https://openalex.org/W2883338879, https://openalex.org/W1515771866, https://openalex.org/W2024669822, https://openalex.org/W298492473, https://openalex.org/W1926161236, https://openalex.org/W2267867442, https://openalex.org/W2377321712, https://openalex.org/W2059247764, https://openalex.org/W2355800873
cited_by_count	0
locations_count	2
best_oa_location.id	doi:10.1158/1078-0432.27033925.v1
best_oa_location.is_oa	True
best_oa_location.source
best_oa_location.license	cc-by
best_oa_location.pdf_url
best_oa_location.version	acceptedVersion
best_oa_location.raw_type	posted-content
best_oa_location.license_id	https://openalex.org/licenses/cc-by
best_oa_location.is_accepted	True
best_oa_location.is_published	False
best_oa_location.raw_source_name
best_oa_location.landing_page_url	https://doi.org/10.1158/1078-0432.27033925.v1
primary_location.id	doi:10.1158/1078-0432.27033925.v1
primary_location.is_oa	True
primary_location.source
primary_location.license	cc-by
primary_location.pdf_url
primary_location.version	acceptedVersion
primary_location.raw_type	posted-content
primary_location.license_id	https://openalex.org/licenses/cc-by
primary_location.is_accepted	True
primary_location.is_published	False
primary_location.raw_source_name
primary_location.landing_page_url	https://doi.org/10.1158/1078-0432.27033925.v1
publication_date	2024-09-16
publication_year	2024
referenced_works_count	0
abstract_inverted_index.METHODS</p>	1
abstract_inverted_index.<p>SUPPLEMENTARY	0
cited_by_percentile_year
countries_distinct_count	0
institutions_distinct_count	17
citation_normalized_percentile.value	0.30814603
citation_normalized_percentile.is_in_top_1_percent	False
citation_normalized_percentile.is_in_top_10_percent	False